News

Tasquinimod works, says Phase II study
Enlarge image

BusinessSwedenFrance

Tasquinimod works, says Phase II study

05.06.2012 - Swedish Active Biotech draws new hope from a Phase II result with prostate cancer drug tasquinimod.

Lund – Almost a year ago Swedish Active Biotech AB saw its stock value dwindling away when the oral multiple sclerosis drug laquinimod failed in crucial Phase III testing. Although the price per share has doubled when compared to the start of the year, SEK44 is still far away from its last 12-month-cycle climax roughly a year ago.

On 4 June, Andrew Armstrong from the Duke Cancer Institute in Durham (USA) presented data on a long-term follow-up of a randomised Phase II placebo-controlled trial with Active Biotech's tasquinimod. The talk, given at the 2012 ASCO Annual Meeting in Chicago (USA), focussed on the median overall survival times of patients suffering from castrate resistant prostate cancer (CRPC) which increased from 30.4 months (placebo) to 33.4 months (tasquinimod). Armstrong expressed that these findings surprised him: "Men with metastatic CRPC in this trial were unexpectedly found to have prolonged survival times, despite a high fraction of patients with liver and lung metastases."  

Active Biotech is developing the drug together with Ipsen group, a pharmaceutical company from Paris (France) employing 4,500 people. Ipsen's CSO Claude Betrand was eager to announce he's pleased with the results: "We are thrilled. The results underline the activity of the compound. With its differentiated mechanism of action [not targeting the androgen receptor pathway] we hope to propose an alternative treatment after the ongoing Phase III results have replicated these interesting findings." So far 600 patients have been recruited for the double-blind Phase III study. In the end the study will include 1,200 patients from more than 250 clinics.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3037.3%
  • GW PHARMACEUTICALS (UK)426.00 GBP667.6%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.28 CHF-91.7%
  • THROMBOGENICS (B)9.14 EUR-70.4%

No liability assumed, Date: 30.07.2014